FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:998-1012 September 2, 2004 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article PubMed Citation

Cutaneous melanoma remains a management challenge. The National Cancer Institute Surveillance, Epidemiology, and End Results (SEER) database documents increases of 619 percent in annual diagnoses of cutaneous melanoma and of 165 percent in annual mortality from 1950 to 2000.¹ In 2004, an estimated 55,000 Americans will receive a diagnosis of cutaneous melanoma, and 7900 will die from the disease.² Of all cancers in the United States, cutaneous melanoma ranks fifth in incidence among men and seventh among women² and is the second leading cause of lost productive years^3,4; it is also the most common cancer among women 20 to . . . [Full Text of this Article]

Melanoma Screening and Identification of High-Risk Persons

Identification of High-Risk Lesions

Staging and Treatment of Primary Melanoma

Nodal Sampling and Staging

Adjuvant Therapy

Treatment of Distant Disease

Future Directions

Source Information

From the Department of Dermatology (H.T., A.J.S.), Massachusetts General Hospital Melanoma Center (H.T., A.J.S.), and the Wellman Center for Photomedicine (H.T.), Massachusetts General Hospital and Harvard Medical School; and the Division of Hematology/Oncology, Department of Medicine, Biologic Therapy and Cutaneous Oncology Programs, Beth Israel Deaconess Medical Center and Harvard Medical School (M.B.A.) — all in Boston.

Address reprint requests to Dr. Tsao at the Department of Dermatology, Massachusetts General Hospital, Bartlett 622, 48 Blossom St., Boston, MA 02114.

Related Letters:

Management of Cutaneous Melanoma
de Giorgi V., Carli P., Giannotti B., Sampsel J. W., Barbera-Guillem E., Miranda E. P., Tsao H., Atkins M. B., Sober A. J.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:2770-2771, Dec 23, 2004. Correspondence

This article has been cited by other articles:

• Begley, J., Ribas, A. (2008). Targeted Therapies to Improve Tumor Immunotherapy. Clin. Cancer Res. 14: 4385-4391 [Abstract] [Full Text]  
• Lo, R. S., Witte, O. N. (2008). Transforming Growth Factor-{beta} Activation Promotes Genetic Context-Dependent Invasion of Immortalized Melanocytes. Cancer Res. 68: 4248-4257 [Abstract] [Full Text]  
• Sosman, J. A., Carrillo, C., Urba, W. J., Flaherty, L., Atkins, M. B., Clark, J. I., Dutcher, J., Margolin, K. A., Mier, J., Gollob, J., Kirkwood, J. M., Panka, D. J., Crosby, N. A., O'Boyle, K., LaFleur, B., Ernstoff, M. S. (2008). Three Phase II Cytokine Working Group Trials of gp100 (210M) Peptide Plus High-Dose Interleukin-2 in Patients With HLA-A2-Positive Advanced Melanoma. JCO 26: 2292-2298 [Abstract] [Full Text]  
• Grange, F., Vitry, F., Granel-Brocard, F., Lipsker, D., Aubin, F., Hedelin, G., Dalac, S., Truchetet, F., Michel, C., Batard, M.-L., Baury, B., Halna, J.-M., Schmutz, J. L., Delvincourt, C., Reuter, G., Dalle, S., Bernard, P., Danzon, A. (2008). Variations in Management of Stage I to Stage III Cutaneous Melanoma: A Population-Based Study of Clinical Practices in France. Arch Dermatol 144: 629-636 [Abstract] [Full Text]  
• Fletcher, J. W., Djulbegovic, B., Soares, H. P., Siegel, B. A., Lowe, V. J., Lyman, G. H., Coleman, R. E., Wahl, R., Paschold, J. C., Avril, N., Einhorn, L. H., Suh, W. W., Samson, D., Delbeke, D., Gorman, M., Shields, A. F. (2008). Recommendations on the Use of 18F-FDG PET in Oncology. JNM 49: 480-508 [Abstract] [Full Text]  
• Rossi, C. R., Mocellin, S., Pasquali, S., Pilati, P., Nitti, D. (2008). N-Ratio: a Novel Independent Prognostic Factor for Patients with Stage-III Cutaneous Melanoma. Ann. Surg. Oncol. 15: 310-315 [Abstract] [Full Text]  
• Gill, S., Shapiro, J., Westerman, D., Prince, H. M. (2007). Long-Term Survival and Secondary Acute Leukemia After Fotemustine Therapy for Metastatic Melanoma. JCO 25: 4493-4494 [Full Text]  
• Ammoury, A. F., El Sayed, F., Bazex, J. (2007). Delayed Wound Healing Following Treatment With Low-Dose Interferon Alfa-2b for Cutaneous Melanoma. Arch Dermatol 143: 1339-1340 [Full Text]  
• Cotter, M. A., Thomas, J., Cassidy, P., Robinette, K., Jenkins, N., Florell, S. R., Leachman, S., Samlowski, W. E., Grossman, D. (2007). N-Acetylcysteine Protects Melanocytes against Oxidative Stress/Damage and Delays Onset of Ultraviolet-Induced Melanoma in Mice. Clin. Cancer Res. 13: 5952-5958 [Abstract] [Full Text]  
• McDermott, D. F., Atkins, M. B. (2007). More Support for the Judicious Use of High-Dose Interleukin-2 in Patients With Advanced Melanoma. JCO 25: 3791-3793 [Full Text]  
• Wang, Y., Dai, D. L., Martinka, M., Li, G. (2007). Prognostic Significance of Nuclear ING3 Expression in Human Cutaneous Melanoma. Clin. Cancer Res. 13: 4111-4116 [Abstract] [Full Text]  
• Ribas, A., Hanson, D. C., Noe, D. A., Millham, R., Guyot, D. J., Bernstein, S. H., Canniff, P. C., Sharma, A., Gomez-Navarro, J. (2007). Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer. The Oncologist 12: 873-883 [Abstract] [Full Text]  
• Bradford, C. R., Levine, P. A. (2007). Incidence and Prognosis of Cutaneous Melanoma Involving the Head and Neck. JAMA 297: 2628-2629 [Full Text]  
• Thomas, J., Liu, T., Cotter, M. A., Florell, S. R., Robinette, K., Hanks, A. N., Grossman, D. (2007). Melanocyte Expression of Survivin Promotes Development and Metastasis of UV-Induced Melanoma in HGF-Transgenic Mice. Cancer Res. 67: 5172-5178 [Abstract] [Full Text]  
• Golger, A., Young, D. S., Ghazarian, D., Neligan, P. C. (2007). Epidemiological Features and Prognostic Factors of Cutaneous Head and Neck Melanoma: A Population-Based Study. Arch Otolaryngol Head Neck Surg 133: 442-447 [Abstract] [Full Text]  
• Zimmerer, J. M., Lesinski, G. B., Kondadasula, S. V., Karpa, V. I., Lehman, A., RayChaudhury, A., Becknell, B., Carson, W. E. III (2007). IFN-{alpha}-Induced Signal Transduction, Gene Expression, and Antitumor Activity of Immune Effector Cells Are Negatively Regulated by Suppressor of Cytokine Signaling Proteins. J. Immunol. 178: 4832-4845 [Abstract] [Full Text]  
• Jiang, W., Mikochik, P. J., Ra, J. H., Lei, H., Flaherty, K. T., Winkler, J. D., Spitz, F. R. (2007). HIV Protease Inhibitor Nelfinavir Inhibits Growth of Human Melanoma Cells by Induction of Cell Cycle Arrest. Cancer Res. 67: 1221-1227 [Abstract] [Full Text]  
• Lesimple, T., Neidhard, E.-M., Vignard, V., Lefeuvre, C., Adamski, H., Labarriere, N., Carsin, A., Monnier, D., Collet, B., Clapisson, G., Birebent, B., Philip, I., Toujas, L., Chokri, M., Quillien, V. (2006). Immunologic and Clinical Effects of Injecting Mature Peptide-Loaded Dendritic Cells by Intralymphatic and Intranodal Routes in Metastatic Melanoma Patients. Clin. Cancer Res. 12: 7380-7388 [Abstract] [Full Text]  
• Blazquez, C., Carracedo, A., Barrado, L., Real, P. J., Fernandez-Luna, J. L., Velasco, G., Malumbres, M., Guzman, M. (2006). Cannabinoid receptors as novel targets for the treatment of melanoma. FASEB J. 20: 2633-2635 [Abstract] [Full Text]  
• Baade, P. D., English, D. R., Youl, P. H., McPherson, M., Elwood, J. M., Aitken, J. F. (2006). The relationship between melanoma thickness and time to diagnosis in a large population-based study.. Arch Dermatol 142: 1422-1427 [Abstract] [Full Text]  
• Gao, L., Feng, Y., Bowers, R., Becker-Hapak, M., Gardner, J., Council, L., Linette, G., Zhao, H., Cornelius, L. A. (2006). Ras-Associated Protein-1 Regulates Extracellular Signal-Regulated Kinase Activation and Migration in Melanoma Cells: Two Processes Important to Melanoma Tumorigenesis and Metastasis. Cancer Res. 66: 7880-7888 [Abstract] [Full Text]  
• Mocellin, S., Ambrosi, A., Montesco, M. C., Foletto, M., Zavagno, G., Nitti, D., Lise, M., Rossi, C. R. (2006). Support Vector Machine Learning Model for the Prediction of Sentinel Node Status in Patients With Cutaneous Melanoma. Ann. Surg. Oncol. 13: 1113-1122 [Abstract] [Full Text]  
• Howell, B G, Lipa, J E, Ghazarian, D M (2006). Intracapsular melanoma: a new pitfall for sentinel lymph node biopsy.. J. Clin. Pathol. 59: 891-892 [Full Text]  
• Tormo, D., Ferrer, A., Gaffal, E., Wenzel, J., Basner-Tschakarjan, E., Steitz, J., Heukamp, L. C., Gutgemann, I., Buettner, R., Malumbres, M., Barbacid, M., Merlino, G., Tuting, T. (2006). Rapid Growth of Invasive Metastatic Melanoma in Carcinogen-Treated Hepatocyte Growth Factor/Scatter Factor-Transgenic Mice Carrying an Oncogenic CDK4 Mutation. Am. J. Pathol. 169: 665-672 [Abstract] [Full Text]  
• Sato, A., Ohtsuki, M., Hata, M., Kobayashi, E., Murakami, T. (2006). Antitumor Activity of IFN-{lambda} in Murine Tumor Models.. J. Immunol. 176: 7686-7694 [Abstract] [Full Text]  
• McCarthy, M. M., DiVito, K. A., Sznol, M., Kovacs, D., Halaban, R., Berger, A. J., Flaherty, K. T., Camp, R. L., Lazova, R., Rimm, D. L., Kluger, H. M. (2006). Expression of tumor necrosis factor-related apoptosis-inducing ligand receptors 1 and 2 in melanoma.. Clin. Cancer Res. 12: 3856-3863 [Abstract] [Full Text]  
• Komori, H., Nakatsura, T., Senju, S., Yoshitake, Y., Motomura, Y., Ikuta, Y., Fukuma, D., Yokomine, K., Harao, M., Beppu, T., Matsui, M., Torigoe, T., Sato, N., Baba, H., Nishimura, Y. (2006). Identification of HLA-A2- or HLA-A24-Restricted CTL Epitopes Possibly Useful for Glypican-3-Specific Immunotherapy of Hepatocellular Carcinoma.. Clin. Cancer Res. 12: 2689-2697 [Abstract] [Full Text]  
• Scala, S., Giuliano, P., Ascierto, P. A., Ierano, C., Franco, R., Napolitano, M., Ottaiano, A., Lombardi, M. L., Luongo, M., Simeone, E., Castiglia, D., Mauro, F., De Michele, I., Calemma, R., Botti, G., Caraco, C., Nicoletti, G., Satriano, R. A., Castello, G. (2006). Human Melanoma Metastases Express Functional CXCR4. Clin. Cancer Res. 12: 2427-2433 [Abstract] [Full Text]  
• Bajetta, E., Del Vecchio, M., Nova, P., Fusi, A., Daponte, A., Sertoli, M. R., Queirolo, P., Taveggia, P., Bernengo, M. G., Legha, S. S., Formisano, B., Cascinelli, N. (2006). Multicenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-{alpha}2b in metastatic melanoma. Ann Oncol 17: 571-577 [Abstract] [Full Text]  
• Reinhardt, M. J., Joe, A. Y., Jaeger, U., Huber, A., Matthies, A., Bucerius, J., Roedel, R., Strunk, H., Bieber, T., Biersack, H.-J., Tuting, T. (2006). Diagnostic Performance of Whole Body Dual Modality 18F-FDG PET/CT Imaging for N- and M-Staging of Malignant Melanoma: Experience With 250 Consecutive Patients. JCO 24: 1178-1187 [Abstract] [Full Text]  
• Dummer, R., Garbe, C., Thompson, J. A., Eggermont, A. M., Yoo, K., Maier, T., Bergstrom, B. (2006). Randomized Dose-Escalation Study Evaluating Peginterferon Alfa-2a in Patients With Metastatic Malignant Melanoma. JCO 24: 1188-1194 [Abstract] [Full Text]  
• Koon, H., Atkins, M. (2006). Autoimmunity and Immunotherapy for Cancer. NEJM 354: 758-760 [Full Text]  
• Tse, K. F., Jeffers, M., Pollack, V. A., McCabe, D. A., Shadish, M. L., Khramtsov, N. V., Hackett, C. S., Shenoy, S. G., Kuang, B., Boldog, F. L., MacDougall, J. R., Rastelli, L., Herrmann, J., Gallo, M., Gazit-Bornstein, G., Senter, P. D., Meyer, D. L., Lichenstein, H. S., LaRochelle, W. J. (2006). CR011, a Fully Human Monoclonal Antibody-Auristatin E Conjugate, for the Treatment of Melanoma. Clin. Cancer Res. 12: 1373-1382 [Abstract] [Full Text]  
• Rossi, C. R., De Salvo, G. L., Trifiro, G., Mocellin, S., Landi, G., Macripo, G., Carcoforo, P., Ricotti, G., Giudice, G., Picciotto, F., Donner, D., Di Filippo, F., Montesco, M. C., Casara, D., Schiavon, M., Foletto, M., Baldini, F., Testori, A. (2006). The Impact of Lymphoscintigraphy Technique on the Outcome of Sentinel Node Biopsy in 1,313 Patients with Cutaneous Melanoma: An Italian Multicentric Study (SOLISM-IMI). JNM 47: 234-241 [Abstract] [Full Text]  
• Panka, D. J., Wang, W., Atkins, M. B., Mier, J. W. (2006). The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells. Cancer Res. 66: 1611-1619 [Abstract] [Full Text]  
• Ascierto, P. A., Scala, S., Castello, G., Daponte, A., Simeone, E., Ottaiano, A., Beneduce, G., De Rosa, V., Izzo, F., Melucci, M. T., Ensor, C. M., Prestayko, A. W., Holtsberg, F. W., Bomalaski, J. S., Clark, M. A., Savaraj, N., Feun, L. G., Logan, T. F. (2005). Pegylated Arginine Deiminase Treatment of Patients With Metastatic Melanoma: Results From Phase I and II Studies. JCO 23: 7660-7668 [Abstract] [Full Text]  
• MacKelfresh, J., Chen, S. C., Monthrope, Y. M. (2005). Pregnancy and Changes in Melanocytic Nevi. Obstet Gynecol 106: 857-860 [Full Text]  
• Wessely, R. (2005). Interference by interferons: Janus faces in vascular proliferative diseases. Cardiovasc Res 66: 433-443 [Abstract] [Full Text]  
• de Giorgi, V., Carli, P., Giannotti, B., Sampsel, J. W., Barbera-Guillem, E., Miranda, E. P., Tsao, H., Atkins, M. B., Sober, A. J. (2004). Management of Cutaneous Melanoma. NEJM 351: 2770-2771 [Full Text]